pS2 protein, EGFR and cathepsin D in association with established prognostic factors in early recurrence of breast cancer

Oncology Research and Treatment

Volumn 19, Issue 2, 1996, Pages 176-180

  Schmidt, R ^a   Sorger, D ^a   Walter, F ^a   Schonfelder M ^a   Preiss, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Breast cancer; Cathepsin D; EGFR (Epidermal growth factor receptor); pS2 Protein

Indexed keywords

CATHEPSIN D; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; PROTEIN PS2; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROGNOSIS;

EID: 0029900141     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218786     Document Type: Article

References (33)

1. Mansour EG, Ravelin PM, Dressier L: Prognostic factors in early breast carcinoma. Cancer 1994:74: 381-400.
2. Sunderland MC. McGuire WL: Oncogenes as clinical prognostic indicators: in Lippman ME. Dickson RB (eels): Regulatory Mechanisms in Breast Cancer. Boston. Kluwer Acad. Publ. 1990. pp 3-22.
3. Dior AD, Koerner FC, Edgerlon SM, Wood WC, Stracher MA, Schwartz LH: pS2 expressin in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 1992:21:111-119.
4. Vizoso F, Sanchez LM, Diez-Itza I, Merino AM, Lopez-Otin C: Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol 1995; 13:54-61.
5. Tandon A, Clark G, Chamness G, Chirgwin J, McGuire W: Cathepsin D and prognosis in breast cancer. N Engl J Med 1990:322:297-302.
6. Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV, Briand P: Altered gene expression of c-nivc. epidermal growth factor receptor, transforming growth factor-α and cerb-B2 in an immortalized human breast epithelial cell line. HMT-3522. is associated with decreased growth factor requirements. Cancer Res 1992:52:1210-1217.
7. Koester SK, Maenpaa JU, Wiebe VJ, Baker WJ, Wurz GT, Seymour RC, Koehler E, DcGrcgorio MW: Flow cytometry: Potential utility in monitoring drug effects in breast cancer. Breast Cancer Res Treat 1994:32:57-65.
8. Foekens JA, Putten WU van, Portengen H, Roden-burg CJ, Reubi JC, Berns PMJJ, Henzen-Logmans SC, Burg MEL van der, Alexieva-Figusch J, Klijn JGM: Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R). insulin-likc growth factor-1 (IGF-l-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol 1990:37:815-821.
9. Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, Yeo R, Ingram D, Dawkin H, Hahnel R, The South Australian Breast Cancer Study Group: The relative prognostic significance of total Cathepsin D and HER-2/ncu oncogene amplification in breast cancer. Int J Cancer 1994:56:61-65.
10. Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987:i: 1398-1402.
11. Koenders PG, Beex LVAM, Kienhuis CBM, Kloppen-borg PWC, Benraad TJ: Epidermal growth factor receptor and prognosis in human breast cancer: A prospective study. Breast Cancer Res Treat 1993: 25:21-27.
12. Ravdin PM: A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. I lematol Oncol Clin North Am 1994:8:197-211.
13. Lowry OH, Rosebrough NJ, Farr A, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chcm 1951:193:265-275.
14. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976:72:248-254.
15. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancers. Eur J Cancer 1980:16:1513-1515.
16. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990:82:1006-1015.
17. Mouridsen HT: Adjuvant systemic therapy in breast cancer. Eur J Cancer 1993:29A:595-598.
18. Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13.
19. Silvestrini R, Vencrono S, Benini E, Di Fronzo G, Daidone M: p53 and Cathepsin are independent of established prognostic factors in breast cancer. Int J Oncol 1992:1:507-512.
20. Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H: A prospective study of the prognostic value of Cathepsin D levels in breast cancer cytosol. Cancer 1993;71:2006-2012.
21. Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM, Bundred NJ, Oates GD, Lee MJR, Neoptolemos JP, Chan SY, Baker PR: Steroid receptors. pS2 and Cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994:30A:5-11.
22. Hahnel E, Robbins P, Harvey J, Sterrett G, Hahnel R: Expression of the pS2 gene in breast tissues assessed by pS2-mRNA analysis and pS2-protcin radioimmunoassay. Breast Cancer Res Treat 1992: 24:71-74.
23. Dookeran K, Rye P, Dearing S, Walker R: Expression of the pS2 peptide in primary breast carcinomas. Comparison of membrane and cytoplasmic staining patterns. J Pathol 1993:171:123-129.
24. Dclvenne CG. Winkler-Gol RA, Piccart MJ, Hustin J, Michaux D, Leclcrcq G, Nogaret JM, Autier P: Expression of c-erbB2. TGF-pl and pS2 genes in primary human breast cancers. Eur J Cancer 1992: 28:700-705.
25. Crombach G, Ingenhorst A, Göhring U, Schaeffer H, Bolle A: pS2 protein in primary breast cancer: in Klapdor R (ed): Tumor Associated Antigens. Oncogenes. Receptors. Cytokines in Tumor Diagnosis and 'Therapy at the Beginning in the Nineties. Cancer of the Breast-State and Trends in Diagnosis and Therapy. München. Zuckschwerdt, 1992. pp 542-545.
26. Foekens J, Rio M, Seguin P, Putten W van, Fauque J, Nap M, Klijn J, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990:50:3832-3837.
27. Cappelletti V, Coradini D, Scanziani E, Benini E, Silvestrini R, Di Fronzo G: Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 1992:28A: 1315-1318.
28. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC Bellocq JP, Chambon P, Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991:51:624-628.
29. Nicholson S, Halcrow P, Farndon J, Sainsbury J, Chambers P, Harris A: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989;i: 182-184.
30. Macias A, Azavedo E, Hägerström T, Klintenberg C, Perez R, Skoog L: Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 1987:7: 459-464.
31. Sliutz G, Zeillinger R, Kurv F, Speiser P, Czerwenka K, Jakesz R, Knogler W, Reiner A, Schneeberger C, Spona J, Zielinski C, Kubista E: EGF-R (epidermal growth factor receptor) in breast cancer and relation to steroid receptors, tumor grading, tumor size, lymph node involvement and age: in Klapdor (ed): Tumor Associated Antigens. Oncogenes. Receptors. Cytokines in Tumor Diagnosis and Therapy in the Beginning of the Nineties. Cancer of the Breast-State and Trends in Diagnosis and Therapy. München, Zuckschwerdt. 1992, pp 392-396.
32. Klijn JGM, Berns PMJJ, Schmitz PIM, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 1992:13:3-17.
33. Wang D, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, Mori T, Fujii S: Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 1993: 72:2628-2637.